Zilia

Mission

To facilitate earlier diagnosis, reduce healthcare costs, and improve the quality of life of patients.

Vision

Developing groundbreaking technology bound to redefine the way we prevent, diagnose, and treat various ocular, neurological, and systemic conditions

Elevator pitch

Existing clinical tools assess existing eye damage By quantifying key biomarkers early, eye care professionals will be able to make earlier diagnoses and better manage eye diseases that can lead to blindness. In addition, since the human eye is a strong indicator of overall health and Zilia’s technology can be adapted to measure many biomarkers present in the eye, other applications are envisaged in fields including neurology, cardiology and oncology.

Description

A rapidly ageing population is contributing to a substantially increased prevalence of eye diseases and associated vision loss. With the goal of enabling early detection and redefining how these conditions are managed, Zilia has developed a revolutionary technological platform that combines imaging, spectrometry and artificial intelligence to measure biomarkers in the human eye. Zilia has launched its first product, Zilia Ocular, the world’s first retinal camera that permits the measurement of oxygen saturation in the eye, a crucial biomarker in the development of the three main causes of blindness: glaucoma, diabetic retinopathy and macular degeneration.

Why do business with us?

In Quebec, Zilia has no direct competitors. Its main international competitors are Oxymap and Imedos. These companies, however, use two-wavelength technologies that permit only single, qualitative, low-precision measurements. These limitations make them unsuitable for clinical use. Zilia’s technology, on the other hand, uses the full spectrum of light to quantify oxygen in real time. As the metabolic activity of the eye is highly adaptive and fluctuating, accurate and continuous measurement of data collected is crucial. Zilia is currently working on obtaining regulatory approvals that will enable the technology to be commercialized in clinics. Despite its major technological edge over the competition, the cost of the Zilia Ocular technology is significantly lower. Currently, Zilia Ocular equipment is sold on the research market at a cost of $80,000, while the competition’s equipment sells for over $150,000.